Expected surge in the Australian Biotech stocks in 2024 with declining interest rates and increasing M&A

Marc Kennis Marc Kennis, December 15, 2023


Australian Biotech stocks could see a massive 2024

Stuart Roberts from Stocks Down Under shares his perspective on the future outlook of Australian biotech stocks.


The US takes the lead

According to Stuart, the sector has evolved favourably over his 20 years of coverage, with companies becoming more adept at setting goals and achieving significant progress. This upward trend is illustrated by the success of Neuren (ASX:NEU), which is now valued beyond $2 billion on ASX following drug approval.

Stuart anticipates a prosperous future for the sector, partially spurred by the United States’ cessation of increasing interest rates. Biotech is typically the first industry to respond positively to such a shift, as it attracts marginal risk capital in American markets. On top of this, the sector is experiencing a wave of acquisitions and mergers, with major pharmaceutical companies buying emerging competitors for substantial sums. These factors culminate in creating fertile ground for potential investors.


Proteomics International Laboratories

Highlighting one promising company, Stuart refers to Proteomics International Laboratories (ASX:PIQ) and their extensive protein database being used to create valuable diagnostics for kidney disease. The company’s first product is approved and selling in multiple jurisdictions. Stuart reveals that his twenty years of experience places him in a prime position to spot such promising entities amongst the ever-evolving biotech landscape.


Our own Stuart Roberts on AusBiz talking Biotechnology



What are the Best Australian Biotech Stocks to invest in right now?

Check our ASX buy/sell tips


Recent Posts

johns lyng group

Johns Lyng Group (ASX:JLG): One of the few ways to profit from climate change

Johns Lyng Group (ASX:JLG) is a restoration services company, repairing properties after damage by insured events, including weather and other…

hydrogen in australia

Hydrogen in Australia: How far away are we from large-scale adoption? And should investors take the plunge now?

When will we see hydrogen in Australia? Not as a fad, not as an idea, but as a widespread energy…

Why is Gina Rinehart buying into Lynas

Why is Gina Rinehart buying into Lynas? She’s accumulated a stake worth over $300m

The big question on many investors’ minds this week is why is Gina Rinehart buying into Lynas? A substantial notice…